Evidence map›Paper›PMID 24587081›Full record

ArticlePloS one2014

Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.

Antonella Cingolani, Alessandro Cozzi-Lepri, Adriana Ammassari, Cristina Mussini, Maria Alessandra Ursitti, Pietro Caramello, Gioacchino Angarano, Paolo Bonfanti, Andrea De Luca, Maria Stella Mura and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 3 countries.

Antonella CingolaniDepartment of Public Health, Institute of Infectious Diseases, Catholic University, Roma, Italy.
Alessandro Cozzi-LepriResearch Department of Infection & Population Health, University College London, London, United Kingdom.
Adriana AmmassariClinical Department, National Institute for Infectious Diseases "L. Spallanzani," Roma, Italy.
Cristina MussiniInstitute of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Maria Alessandra UrsittiDepartment of Infectious Diseases, S. Maria Nuova IRCCS Hospital, Reggio Emilia, Italy.
Pietro CaramelloInfectious and Tropical Diseases Unit I, Department of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy.
Gioacchino AngaranoDepartment of Infectious Diseases, University of Bari, Bari, Italy.
Paolo BonfantiUnit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy.
Andrea De LucaDepartment of Internal and Specialty Medicine, University Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Maria Stella MuraDepartment of Infectious Diseases, University of Sassari, Sassari, Italy.
Enrico GirardiDepartment of Epidemiology, National Institute for Infectious Diseases "L. Spallanzani," Roma, Italy.
Andrea AntinoriClinical Department, National Institute for Infectious Diseases "L. Spallanzani," Roma, Italy.
Antonela D'Arminio MonforteDepartment of Medicine, Surgery and Dentistry University of Milan Clinic of Infectious Diseases, "San Paolo" Hospital, Milan, Italy.
Icona Foundation Study group
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITAlessandro Manzoni Hospital · ITAzienda Ospedaliera Universitaria Senese · ITCatholic University of America · USIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale Amedeo di Savoia · ITUniversity College London · GBUniversity of Bari Aldo Moro · ITUniversity of Modena and Reggio Emilia · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTime of starting antiretroviral therapy (ART) after diagnosis of specific AIDS-defining event (ADE) is a crucial aspect. Objectives of this study were to evaluate if in patients diagnosed with ADE the time to ART initiation may vary according to year of diagnosis and type of ADE.

methodsAll HIV+ persons diagnosed with an ADE over the 6 months prior to or after enrolment in the Icona Foundation study cohort and while ART-naive were grouped according to type of diagnosis: Those with ADE requiring medications interacting with ART [group A], those with ADE treatable only with ART [B] and other ADE [C]. Survival analysis by Kaplan-Meier was used to estimate the percentage of people starting ART, overall and after stratification for calendar period and ADE group. Multivariable Cox regression model was used to investigate association between calendar year of specific ADE and time to ART initiation.

results720 persons with first ADE were observed over 1996-2013 (group A, n=171; B, n=115; C, n=434). By 30 days from diagnosis, 27% (95% CI: 22-32) of those diagnosed in 1996-2000 had started ART vs. 32% (95% CI: 24-40) in 2001-2008 and 43% (95% CI: 33-47) after 2008 (log-rank p=0.001). The proportion of patients starting ART by 30 days was 13% (95% CI 7-19), 40% (95% CI: 30-50) and 38% (95% CI 33-43) in ADE groups A, B and C (log-rank p=0.0001). After adjustment for potential confounders, people diagnosed after 2008 remained at increased probability of starting ART more promptly than those diagnosed in 1996-1999 (AHR 1.72 (95% CI 1.16-2.56).

conclusionsIn our "real-life" setting, the time from ADE to ART initiation was significantly shorter in people diagnosed in more recent years, although perhaps less prompt than expected.

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedTime FactorsAnti-HIV Agents

Identifiers

PMID24587081
PMCPMC3937396
OpenAlexW2102088786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.